This finding indicates a great need for further investigation of ROR1, not only in lymphoma, but also in AML, and suggests that combined targeting of ROR1 (e.g., cirmtuzumab) and BCL2 (e.g., venetoclax) might be worth considering. Here, ROR1 is linked to lymphoma.